Prognostic impact of neoadjuvant therapy vs upfront surgery in patients with huge hepatocellular carcinoma undergoing curative resection
World Journal of Gastroenterology · 2027-01-14 · 33 (2)
DOI: 10.3748/wjg.122833 ↗Abstract
BACKGROUND Huge hepatocellular carcinoma (HCC) is associated with a high postoperative recurrence rate and poor long-term survival. The role of neoadjuvant therapy in patients with huge HCC eligible for curative resection remains uncertain. AIM To compare long-term outcomes after neoadjuvant therapy vs upfront surgery in huge HCC. METHODS This single-center retrospective surgical cohort study included patients with huge HCC who underwent curative liver resection from January 2019 to November 2024. Huge HCC was defined as a maximum tumor diameter ≥ 10 cm on pre-treatment enhanced computed tomography or magnetic resonance imaging. Patients were divided into neoadjuvant therapy and upfront surgery groups. The primary endpoint was recurrence-free survival (RFS), with overall survival (OS) and surgery-related outcomes as secondary endpoints. RESULTS A total of 103 patients were included, with 56 in the neoadjuvant therapy group and 47 in the upfront surgery group. After a median follow-up of 30 months, the RFS and OS rates in the neoadjuvant therapy group were superior to those in the upfront surgery group. The 1-year and 3-year RFS rates were 76.8% vs 55.3% and 59.2% vs 41.5%, respectively. The corresponding 1-year and 3-year OS rates were 98.2% vs 87.2% and 88.9% vs 71.7%, respectively. Multivariable analysis identified upfront surgery and lack of postoperative adjuvant therapy as independent risk factors for poorer RFS and OS. Surgery-related outcomes were comparable between groups. CONCLUSION In this retrospective surgical cohort study, neoadjuvant therapy was associated with improved survival without significantly increasing perioperative burden in patients with huge HCC.
EUVIMED